nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CTSG—cardiovascular system—attention deficit hyperactivity disorder	0.0313	0.052	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—attention deficit hyperactivity disorder	0.03	0.05	CbGeAlD
Bortezomib—PSMD2—forebrain—attention deficit hyperactivity disorder	0.0264	0.0439	CbGeAlD
Bortezomib—PSMD2—cardiovascular system—attention deficit hyperactivity disorder	0.0223	0.0372	CbGeAlD
Bortezomib—PSMB2—forebrain—attention deficit hyperactivity disorder	0.0198	0.0329	CbGeAlD
Bortezomib—PSMD1—midbrain—attention deficit hyperactivity disorder	0.0197	0.0328	CbGeAlD
Bortezomib—PSMA1—nervous system—attention deficit hyperactivity disorder	0.0193	0.0321	CbGeAlD
Bortezomib—PSMA1—central nervous system—attention deficit hyperactivity disorder	0.0185	0.0309	CbGeAlD
Bortezomib—PSMA1—cerebellum—attention deficit hyperactivity disorder	0.0181	0.0302	CbGeAlD
Bortezomib—PSMD2—midbrain—attention deficit hyperactivity disorder	0.0174	0.029	CbGeAlD
Bortezomib—PSMB1—cardiovascular system—attention deficit hyperactivity disorder	0.0171	0.0285	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—attention deficit hyperactivity disorder	0.0167	0.0278	CbGeAlD
Bortezomib—PSMB5—midbrain—attention deficit hyperactivity disorder	0.0153	0.0255	CbGeAlD
Bortezomib—PSMD1—cerebellum—attention deficit hyperactivity disorder	0.0152	0.0253	CbGeAlD
Bortezomib—PSMA1—brain—attention deficit hyperactivity disorder	0.0147	0.0245	CbGeAlD
Bortezomib—PSMD2—nervous system—attention deficit hyperactivity disorder	0.0143	0.0239	CbGeAlD
Bortezomib—PSMD2—central nervous system—attention deficit hyperactivity disorder	0.0138	0.023	CbGeAlD
Bortezomib—PSMD2—cerebellum—attention deficit hyperactivity disorder	0.0135	0.0224	CbGeAlD
Bortezomib—PSMB1—midbrain—attention deficit hyperactivity disorder	0.0134	0.0223	CbGeAlD
Bortezomib—PSMB2—midbrain—attention deficit hyperactivity disorder	0.013	0.0217	CbGeAlD
Bortezomib—PSMD1—brain—attention deficit hyperactivity disorder	0.0124	0.0206	CbGeAlD
Bortezomib—PSMB5—cerebellum—attention deficit hyperactivity disorder	0.0118	0.0197	CbGeAlD
Bortezomib—SLC31A1—midbrain—attention deficit hyperactivity disorder	0.0113	0.0188	CbGeAlD
Bortezomib—PSMB1—nervous system—attention deficit hyperactivity disorder	0.011	0.0183	CbGeAlD
Bortezomib—PSMD2—brain—attention deficit hyperactivity disorder	0.011	0.0182	CbGeAlD
Bortezomib—PSMB8—brain—attention deficit hyperactivity disorder	0.0109	0.0181	CbGeAlD
Bortezomib—PSMB2—nervous system—attention deficit hyperactivity disorder	0.0107	0.0179	CbGeAlD
Bortezomib—PSMB1—central nervous system—attention deficit hyperactivity disorder	0.0106	0.0176	CbGeAlD
Bortezomib—PSMB1—cerebellum—attention deficit hyperactivity disorder	0.0103	0.0172	CbGeAlD
Bortezomib—PSMB2—central nervous system—attention deficit hyperactivity disorder	0.0103	0.0172	CbGeAlD
Bortezomib—PSMB2—cerebellum—attention deficit hyperactivity disorder	0.0101	0.0168	CbGeAlD
Bortezomib—PSMB5—brain—attention deficit hyperactivity disorder	0.00961	0.016	CbGeAlD
Bortezomib—SLC31A1—nervous system—attention deficit hyperactivity disorder	0.00929	0.0155	CbGeAlD
Bortezomib—SLC31A1—central nervous system—attention deficit hyperactivity disorder	0.00894	0.0149	CbGeAlD
Bortezomib—SLC31A1—cerebellum—attention deficit hyperactivity disorder	0.00874	0.0146	CbGeAlD
Bortezomib—PSMB1—brain—attention deficit hyperactivity disorder	0.0084	0.014	CbGeAlD
Bortezomib—PSMB2—brain—attention deficit hyperactivity disorder	0.0082	0.0137	CbGeAlD
Bortezomib—SLC31A1—brain—attention deficit hyperactivity disorder	0.0071	0.0118	CbGeAlD
Bortezomib—PTGS1—forebrain—attention deficit hyperactivity disorder	0.00511	0.0085	CbGeAlD
Bortezomib—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00473	0.00787	CbGeAlD
Bortezomib—PTGS1—cardiovascular system—attention deficit hyperactivity disorder	0.00432	0.00719	CbGeAlD
Bortezomib—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.0042	0.00699	CbGeAlD
Bortezomib—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.00315	0.00525	CbGeAlD
Bortezomib—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.00304	0.00506	CbGeAlD
Bortezomib—PTGS1—nervous system—attention deficit hyperactivity disorder	0.00277	0.00461	CbGeAlD
Bortezomib—PTGS1—central nervous system—attention deficit hyperactivity disorder	0.00267	0.00444	CbGeAlD
Bortezomib—CYP2C8—brain—attention deficit hyperactivity disorder	0.00261	0.00435	CbGeAlD
Bortezomib—CYP1A1—brain—attention deficit hyperactivity disorder	0.00241	0.00402	CbGeAlD
Bortezomib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00232	0.00385	CbGeAlD
Bortezomib—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00228	0.00379	CbGeAlD
Bortezomib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00223	0.00371	CbGeAlD
Bortezomib—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00219	0.00365	CbGeAlD
Bortezomib—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00214	0.00357	CbGeAlD
Bortezomib—PTGS1—brain—attention deficit hyperactivity disorder	0.00212	0.00353	CbGeAlD
Bortezomib—CYP2D6—brain—attention deficit hyperactivity disorder	0.00174	0.0029	CbGeAlD
Bortezomib—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000445	0.00112	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000444	0.00111	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000442	0.00111	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000433	0.00109	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000433	0.00109	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000425	0.00106	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000423	0.00106	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000421	0.00105	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000417	0.00104	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000417	0.00104	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000416	0.00104	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000416	0.00104	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000416	0.00104	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000415	0.00104	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000412	0.00103	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000412	0.00103	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00041	0.00103	CbGpPWpGaD
Bortezomib—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00041	0.00103	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000409	0.00102	CbGpPWpGaD
Bortezomib—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000406	0.00102	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000404	0.00101	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SNAP25—attention deficit hyperactivity disorder	0.000404	0.00101	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000404	0.00101	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000401	0.001	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000399	0.001	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SNAP25—attention deficit hyperactivity disorder	0.000398	0.000997	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000397	0.000995	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000394	0.000986	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000394	0.000986	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000394	0.000986	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000388	0.000973	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000387	0.000969	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000387	0.000969	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000387	0.000969	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000381	0.000955	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000377	0.000945	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000376	0.000941	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000374	0.000936	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000373	0.000934	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000371	0.00093	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00037	0.000925	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000361	0.000905	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00036	0.0009	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000358	0.000896	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000355	0.000889	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000353	0.000885	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000352	0.000881	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000352	0.000881	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000351	0.000878	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000349	0.000875	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000349	0.000874	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000348	0.000871	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000348	0.000871	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000348	0.000871	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000347	0.00087	CbGpPWpGaD
Bortezomib—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000347	0.000869	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000343	0.000859	CbGpPWpGaD
Bortezomib—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000338	0.000847	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000338	0.000847	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000338	0.000847	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000338	0.000847	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000338	0.000847	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000337	0.000845	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000336	0.000843	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000336	0.000841	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000336	0.000841	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000335	0.000839	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000334	0.000837	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000334	0.000837	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000333	0.000835	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000333	0.000833	CbGpPWpGaD
Bortezomib—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000331	0.000829	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000327	0.000818	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000325	0.000814	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000324	0.00081	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000322	0.000806	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000322	0.000806	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000322	0.000806	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00032	0.000802	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000317	0.000795	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000304	0.000761	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000304	0.000761	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000304	0.000761	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.0003	0.000751	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000286	0.000716	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000286	0.000716	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000286	0.000716	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000283	0.000708	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000283	0.000708	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000283	0.000708	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000282	0.000706	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000279	0.000698	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000274	0.000686	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000274	0.000686	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000274	0.000686	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000272	0.00068	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00027	0.000676	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00027	0.000675	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000269	0.000674	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000269	0.000674	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000269	0.000674	CbGpPWpGaD
Bortezomib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000268	0.000671	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000266	0.000666	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000266	0.000666	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000266	0.000666	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000265	0.000664	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000262	0.000656	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000256	0.000642	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000256	0.000642	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000256	0.000642	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000256	0.00064	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000256	0.00064	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000256	0.00064	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000254	0.000637	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000254	0.000637	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000254	0.000637	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000253	0.000633	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000252	0.000631	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000251	0.000628	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000248	0.00062	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000248	0.00062	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000248	0.00062	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000244	0.000611	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000229	0.000573	CbGpPWpGaD
Bortezomib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000228	0.000571	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000228	0.00057	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000227	0.000568	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000226	0.000565	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000221	0.000554	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000221	0.000554	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000218	0.000545	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000207	0.000518	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000202	0.000506	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EP300—attention deficit hyperactivity disorder	0.000188	0.00047	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EP300—attention deficit hyperactivity disorder	0.000187	0.000467	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EP300—attention deficit hyperactivity disorder	0.000186	0.000465	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000185	0.000462	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000177	0.000443	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000173	0.000434	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000173	0.000434	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000173	0.000434	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EP300—attention deficit hyperactivity disorder	0.000173	0.000434	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EP300—attention deficit hyperactivity disorder	0.000172	0.000431	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EP300—attention deficit hyperactivity disorder	0.000171	0.000429	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000171	0.000428	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00017	0.000425	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000168	0.000422	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000168	0.000421	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000156	0.00039	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000156	0.00039	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000153	0.000384	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000145	0.000363	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000144	0.000361	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000144	0.00036	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000144	0.00036	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000143	0.000358	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000143	0.000358	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000142	0.000357	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EP300—attention deficit hyperactivity disorder	0.000142	0.000356	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EP300—attention deficit hyperactivity disorder	0.000142	0.000356	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EP300—attention deficit hyperactivity disorder	0.000142	0.000356	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000141	0.000352	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EP300—attention deficit hyperactivity disorder	0.00014	0.000351	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000134	0.000335	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000133	0.000333	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EP300—attention deficit hyperactivity disorder	0.000131	0.000329	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EP300—attention deficit hyperactivity disorder	0.000131	0.000329	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EP300—attention deficit hyperactivity disorder	0.000131	0.000329	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000131	0.000327	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EP300—attention deficit hyperactivity disorder	0.000129	0.000324	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000129	0.000323	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000127	0.000319	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000127	0.000319	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000125	0.000314	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000125	0.000312	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000121	0.000304	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000121	0.000302	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00012	0.000301	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000119	0.000297	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000117	0.000294	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000117	0.000294	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000117	0.000292	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000116	0.000291	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000116	0.000291	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000115	0.000289	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000114	0.000286	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000114	0.000286	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000111	0.000278	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—attention deficit hyperactivity disorder	0.00011	0.000275	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—attention deficit hyperactivity disorder	0.00011	0.000275	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—attention deficit hyperactivity disorder	0.00011	0.000275	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000109	0.000272	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000108	0.000271	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000107	0.000269	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000106	0.000266	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000102	0.000255	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	9.93e-05	0.000249	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.93e-05	0.000249	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	9.77e-05	0.000245	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.7e-05	0.000243	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	9.44e-05	0.000236	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.37e-05	0.000235	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	9.37e-05	0.000235	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.29e-05	0.000233	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.19e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.19e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.19e-05	0.00023	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.09e-05	0.000228	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.08e-05	0.000227	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.06e-05	0.000227	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.92e-05	0.000223	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.85e-05	0.000221	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	8.65e-05	0.000217	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	8.59e-05	0.000215	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.33e-05	0.000209	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.94e-05	0.000199	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	7.72e-05	0.000193	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	7.67e-05	0.000192	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	7.67e-05	0.000192	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.67e-05	0.000192	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.56e-05	0.000189	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	7.54e-05	0.000189	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.44e-05	0.000186	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	7.1e-05	0.000178	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	7.05e-05	0.000177	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	7.04e-05	0.000176	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.01e-05	0.000176	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	6.99e-05	0.000175	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.78e-05	0.00017	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.13e-05	0.000153	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	6.02e-05	0.000151	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	5.98e-05	0.00015	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.83e-05	0.000146	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	5.79e-05	0.000145	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—attention deficit hyperactivity disorder	5.74e-05	0.000144	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	4.64e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	4.61e-05	0.000115	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	4.05e-05	0.000101	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	3.71e-05	9.29e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	3.31e-05	8.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.05e-05	7.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	3.02e-05	7.56e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	2.58e-05	6.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.99e-05	4.99e-05	CbGpPWpGaD
